Myriad Genetics
MYGN
246 hedge funds and large institutions have $2.48B invested in Myriad Genetics in 2024 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 86 increasing their positions, 72 reducing their positions, and 23 closing their positions.
146% more call options, than puts
Call options by funds: $3.04M | Put options by funds: $1.24M
104% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 23
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
19% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 72
10% more funds holding
Funds holding: 223 → 246 (+23)
10% more capital invested
Capital invested by funds: $2.25B → $2.48B (+$229M)
1.99% less ownership
Funds ownership: 101.87% → 99.88% (-2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$35.9M |
| 2 |
Millennium Management
New York
|
+$21M |
| 3 |
DGI
Disciplined Growth Investors
Minneapolis,
Minnesota
|
+$11.9M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$11.9M |
| 5 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Glenview Capital Management
New York
|
-$67.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$45.9M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$42M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$41.8M |
| 5 |
Morgan Stanley
New York
|
-$13.3M |
MYGN Hedge Fund Activity: Q3 2024 in Review
246 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q3 2024, worth a combined $2.48B — up 10% from $2.25B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new MYGN positions and 23 closed out — a net gain of 24 holders — while 86 added to existing stakes and 72 trimmed.
The largest buyer was Loomis, Sayles & Company, adding an estimated $35.9M. The largest seller was Glenview Capital Management, cutting an estimated $67.3M.
- 246 institutional investors held Myriad Genetics (MYGN) as of Q3 2024, up from 223 in Q2 2024.
- Funds reported $2.48B of Myriad Genetics stock for Q3 2024, up 10% quarter-over-quarter.
- 47 funds opened new Myriad Genetics positions in Q3 2024 and 23 closed out, a net change of +24 holders.
- The largest Myriad Genetics buyer in Q3 2024 was Loomis, Sayles & Company, an estimated $35.9M added.
- The largest Myriad Genetics seller in Q3 2024 was Glenview Capital Management, an estimated $67.3M sold.
Based on aggregated 13F filings for Q3 2024.